Search clinical trials for: Active Comparator: GARDASIL ®9

Total 6602 results

Boston Medical Center
Merck Sharp & Dohme LLC

Recruiting

Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old, An Exploratory Immunogenicity Study

Human Papilloma Virus

United States
Shanghai Bovax Biotechnology Co., Ltd.
Chongqing Bovax Biopharmaceutical Co., Ltd.

Completed

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | CIN1 | CIN2 | CIN3 | VaIN1 | VaIN2 | VaIN3 | Genital Wart | VIN 1 | VIN 2 | VIN 3 | AIS | HPV Infections

China
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9

Cervical Cancer | Papillomavirus Infections | CIN | Genital Wart | VIN

China
Laval University
Centers for Disease Control and Prevention

Completed

Immunogenicity of One Dose of Gardasil and One Dose of Gardasil-9

Human Papillomavirus Vaccines

Canada
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)

Papillomavirus Infections

Japan
Boston Medical Center
Merck Sharp & Dohme LLC

Recruiting

An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen

HPV Infection

United States
Western Institute for Veterans Research
Merck Sharp & Dohme LLC; University of Utah

Recruiting

Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts

Warts

United States
London School of Hygiene and Tropical Medicine
Merck Sharp & Dohme LLC; Public Health England; University of Cambridge

Active, not recruiting

HPV Vaccination in Africa- New Delivery Schedules Alias The HANDS HPV Vaccine Trial (HPV)

Human Papillomavirus Vaccine

Gambia
Merck Sharp & Dohme LLC

Completed

An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)

Papillomavirus Infections
Columbia University
Merck Sharp & Dohme LLC; Jhpiego

Active, not recruiting

HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini

Hiv | HPV Infection | HPV Vaccine

Swaziland
Centre Hospitalier Universitaire de la Réunion

Completed

Study of the Impact of a School Program Combining - Promotion of HPV Vaccination and HPV Vaccine Offer in Middle School - on Adherence to HPV Vaccination in Middle School Students (PROM SSCOL)

Papilloma Viral Infection

France
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

Papillomavirus Infections

United States, Belgium, Brazil, Colombia, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Spain, Taiwan, Thailand
Eastern Virginia Medical School
Merck Sharp & Dohme LLC

Recruiting

Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination

Papillomavirus Vaccines

United States
Xiamen University
Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...

Not yet recruiting

Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women

Cervical Cancer | Condylomata Acuminata

China
University Health Network, Toronto
Merck Sharp & Dohme LLC

Not yet recruiting

HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL

Anal Cancer | Human Papilloma Virus | Anal Intraepithelial Neoplasia

Canada
National Institute of Allergy and Infectious Diseases...

Recruiting

Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

Idiopathic CD4 T Cell Lymphocytopenia

United States
Xiamen University
Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...

Completed

Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age

Cervical Cancer | Condylomata Acuminata

China
Sinocelltech Ltd.

Recruiting

A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years

Randomized | Prevention | Interventional

China
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy, Immunogenicity, and Safety Study of the 9vHPV Vaccine in Japanese Males (V503-064)

Warts, Genital | Neoplasms, Anal

Japan
Milton S. Hershey Medical Center

Withdrawn

HPV Vaccine in Postpartum Women

HPV Infection
Clinical Nutrition Research Center, Illinois Institute...

Completed

Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose Tolerance (GSE3)

Impaired Glucose Tolerance

United States
Louisiana State University Health Sciences Center...
Merck Sharp & Dohme LLC

Recruiting

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV (AGO-Gard)

Cervical Intraepithelial Neoplasia | Human Immunodeficiency Virus | Anal Intraepithelial Neoplasia | Papillomavirus Infection | Papillomavirus Vaccines | Serology | Oral Cavity Infection

United States
Laval University

Completed

Immunogenicity and Safety of Gardasil-9 and Cervarix

HPV Vaccines Immunogenicity and Safety

Canada
Medical College of Wisconsin
Merck Sharp & Dohme LLC

Recruiting

Immunogenicity of HPV Vaccine in Transplant Recipients.

Chronic Kidney Diseases | Kidney Transplant

United States
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)

Uterine Cervical Neoplasms | Papillomavirus Infections | Vulvar Neoplasms | Vaginal Neoplasms | Condylomata Acuminata | Adenocarcinoma in Situ

Vietnam
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Papillomavirus Infections | Coronavirus Disease (COVID-19)

United States
Merck Sharp & Dohme LLC

Completed

Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Human Papillomavirus Infection | Genital Warts
Merck Sharp & Dohme LLC

Active, not recruiting

Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)

Genital Warts

China
Miquel Angel Pavon Ribas
Catalan Institute of Health; Hospital del Mar

Recruiting

A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV) (RIFT-HPV)

Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III) | Human Papillomavirus (HPV) Infections | High-risk HPV | HPV-16/ 18

Spain
Sheba Medical Center

Withdrawn

The Effect of Algae Dunaliella Bardawil on Psoriasis (2)

Psoriasis

Israel
Partha Basu
All India Institute of Medical Sciences, New Delhi; Tata Memorial Centre; Deutsches... and other collaborators

Active, not recruiting

Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India

Cervical Cancer | Cervical Precancerous Lesions

India
Massachusetts General Hospital
Bill and Melinda Gates Foundation; Kenya Medical Research Institute

Active, not recruiting

The KEN SHE Study on HPV-vaccine Efficacy

Papillomavirus Infections

Kenya
Sinocelltech Ltd.

Recruiting

A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years

HPV Infection Vaccine Safety SCT1000

China
Imperial College London

Not yet recruiting

Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative The NOVEL Trial (NOVEL)

Neoplasia
Shanghai Bovax Biotechnology Co., Ltd.

Recruiting

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | CIN1 | CIN2 | CIN3 | VaIN1 | VaIN2 | VaIN3 | Genital Wart | VIN 1 | VIN 2 | VIN 3 | AIS

China
Merck Sharp & Dohme LLC

Completed

A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)

Papillomavirus Infections | Human
Shanghai Bovax Biotechnology Co., Ltd.
Chongqing Bovax Biopharmaceutical Co., Ltd.

Completed

Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | CIN1 | CIN2 | CIN3 | VaIN1 | VaIN2 | VaIN3 | Genital Wart | VIN 1 | VIN 2 | VIN 3 | AIS

China
Universitaire Ziekenhuizen KU Leuven

Completed

Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients

Hiv | Human Papilloma Virus | Organ Transplants

Belgium
Erasmus Medical Center
Dutch Cancer Society

Not yet recruiting

Adjuvant Nonavalent HPV Vaccination in Women Treated for Vulvar HSIL (VulVaccin)

HPV | Vulvar HSIL

Netherlands
PharmaJet, Inc.
National Cancer Institute (NCI); National Institutes of Health (NIH)

Not yet recruiting

Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System

Vaccine Reaction

Indonesia
PATH
International Centre for Diarrhoeal Disease Research, Bangladesh; The Emmes... and other collaborators

Completed

Phase 3 Trial of a Bivalent HPV Vaccine (Cecolin®) in Young Girls

Cervical Cancer

Bangladesh, Ghana
Merck Sharp & Dohme LLC

Completed

Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)

Neoplasms, Glandular and Epithelial | Whooping Cough | Tetanus | Diphtheria | Meningitis
Beijing Health Guard Biotechnology, Inc
National Institutes for Food and Drug Control, China; Yunnan Center for Disease... and other collaborators

Active, not recruiting

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Human Papillomavirus Infection

China
University of British Columbia
Merck Canada Inc.

Completed

Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine (Merck08)

Human Papillomavirus

Canada
University of Alabama at Birmingham
Merck Investigator Studies Program

Not yet recruiting

Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department

Human Papilloma Virus

United States
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Human Papillomavirus Infection | Genital Warts

Austria, Belgium, Finland, Germany, Italy, Spain
Murdoch Childrens Research Institute
London School of Hygiene and Tropical Medicine; National Institute of Hygiene...

Completed

HPV Vaccine Immunity in High-risk Women

HPV Infection

Vietnam
London School of Hygiene and Tropical Medicine
National Institute for Medical Research, Tanzania; Ocean Road Cancer Institute... and other collaborators

Completed

Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls

Cervical Cancer

Tanzania
Merck Sharp & Dohme LLC
National Institute of Allergy and Infectious Diseases (NIAID); HIV Vaccine...

Completed

A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)

HIV Infections | HIV-1
CHU de Reims

Completed

Comparing Health Services Interventions for the Prevention of HPV-related Cancer (CoheaHr-WP4)

Cervical Cancer

France

Search clinical trials for: Active Comparator: GARDASIL ®9

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations